CURE’s non-Hodgkin lymphoma (NHL) page is an extensive resource of cancer information featuring the latest NHL news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on non-Hodgkin lymphoma.
December 23rd 2021
New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.
December 21st 2021
“I had to choose one of two paths, to become the victim and let the disease control me or take control of the disease and fight for my life. The moment I chose to fight was the moment life opened all of its beauty,” writes a lymphoma survivor.
December 17th 2021
A non-Hodgkin’s lymphoma survivor writes about how she chose to approach a stressful doctor’s appointment and how doing whatever helps may look different for everyone.
December 12th 2021
Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.
November 26th 2021
Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.
November 18th 2021
Although the interest of at-home care including the administration of cancer infusions has grown since the start of the COVID-19 pandemic, hesitation looms over its convenience, cost and safety.
November 1st 2021
The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.
October 7th 2021
Caregivers of patients with cancer may face financial toxicity and stress — with little time to take care of themselves.
September 23rd 2021
The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.
September 22nd 2021
The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.
September 1st 2021
The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.
August 6th 2021
A survivor shares how she chose to approach her mindset during cancer treatments to keep herself from spiraling.
July 29th 2021
Bayer, the manufacturer of Roundup, created a five-point plan to decrease the risk of facing future litigation about its product causing cancer.
July 26th 2021
About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.
July 16th 2021
From Ashley Monroe’s blood cancer diagnosis to a CrossFit athlete’s inspiring cancer journey, here’s what’s happening in the cancer landscape this week.
July 9th 2021
Do you keep your job? Your friends? One cancer survivor discusses her decisions after being told her non-Hodgkin lymphoma was in remission.
July 8th 2021
In this episode of the “CURE® Talks Cancer” podcast, a cancer survivor explains how she took a lighthearted and comedic approach to her cancer treatment process and went on to create a coloring book based on the funny thoughts she had.
June 6th 2021
Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.
January 14th 2021
The Food and Drug Administration approved the supplemental new drug application for Xalkori (crizotinib) to treat children and young adults between the ages of 1 and 21 with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma.
January 6th 2021
The FDA has not yet reached a decision on an application for the approval of a CAR-T cell therapy product for the treatment of relapsed/refractory large b-cell lymphoma and, according to Bristol Myers Squibb, a new action date for the decision has not been set.
December 18th 2020
From a new study showing data that patients with cancer, especially Black patients with cancer, are at a higher risk for COVID-19 than non-cancer patients to NFL punter Rigoberto Sanchez making a speedy recovery after surgery for cancer, here’s what’s happening in the cancer space this week.
December 17th 2020
For multiple patients with blood cancers who would normally use Rituxan, the Food and Drug Administration has approved the biosimilar Riabni based off highly similar clinical evidence between the two drugs, potentially lowering costs for patients.
December 17th 2020
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.
December 8th 2020
In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.
December 6th 2020
The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
December 2nd 2020
Safety and efficacy observed in this real-world study for patients with non-Hodgkin lymphoma similarly reflect findings from previous pivotal trials.
December 2nd 2020
A novel type of immunotherapy known as chimeric antigen receptor, or CAR, T cell therapy is a hot topic in the news and in the lab. But what does this treatment consist of, and how was it developed?